title: Administration of palivizumab: a medical provider's perspective.
authors.affiliation: Department of Pediatrics, Division of General Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland 21201-1512, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Helm
authors.forename: Ginny E
authors.initials: GE
authors.lastname: Cummings
authors.forename: Virginia
authors.initials: V
authors.lastname: Keane
authors.forename: James C
authors.initials: JC
authors.lastname: King
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007348:Insurance, Health / Q000191:economics / Q000706:statistics & numerical data; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab